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A B S T R A C T
We report a case of a 59-year-old woman with peritoneal malignant mesothelioma and no previous exposure to
asbestos with a diagnosis of bilateral ovarian serous borderline tumour with peritoneal implants one year before.
We discuss the histopathological and immunohistochemical findings to explain possible and potential interac-
tions between the two diseases. To our knowledge, the association of both serous borderline ovarian tumour and
malignant peritoneal mesothelioma has never been described before in the same woman and in such a tight
temporal connection. This finding raises numerous issues about the origin of the two tumours and further
biomolecular studies are needed to fully understand the carcinogenetic process. From a clinical point of view,
this case report can be useful to gynaecologists because it leads to recommend a careful examination of the
peritoneal cavity during a surgical resection of borderline serous tumour. Moreover, it may suggest performing a
close follow-up associated with a careful surveillance of the patient, especially in the case of micropapillary
pattern, to oncologists. A complete clinical approach could help to detect sooner possible relapses or other
metachronous malignancies.
1. Introduction
Malignant peritoneal mesothelioma is a fatal and aggressive disease
and the clinical and morphological distinction from serous ovarian
neoplasms can be difficult. Ovarian serous borderline tumour is usually
confined to the ovary and has an indolent course; however, certain
clinicopathological features, such as the presence of a micropapillary
pattern, microinvasion and extraovarian implants have been linked to a
more aggressive disease (Malpica and Wong, 2016).
In this manuscript, we describe a case of malignant peritoneal me-
sothelioma in a woman with bilateral ovarian serous borderline tu-
mour. To our knowledge, the association of these two pathologies has
not yet been reported in previous articles.
2. Clinical history
A 59-year-old woman with no family history of cancer, an unknown
BRCA status and no previous exposure to asbestos was referred to our
hospital for abdominal pain and large bowel obstruction. One year prior
to this referral, she underwent a previous surgery consisting in bilateral
salpingo-oophorectomy with removal of a macroscopically unharmed
omental flap measuring approximately 8 cm×5 cm×1 cm. The pa-
tient had a pre-surgical interview and refused to undergo a more radical
treatment. For this reason the uterus was left in place. The diagnosis of
bilateral serous borderline ovarian tumour (SBOT) with micropapillary
pattern (Fig. 1), with an additional surface component was made. Non
invasive implants located in the omentum flap were found on random
biopsies and observed only at the microscopical examination. The stage
of tumour was III2A according to the recent Prat et al. (2017). At the
end of the surgery no macroscopical residual disease remained. No type
of surveillance has been made to the patient. Post operative treatment
was not given because the patient refused additional therapy.
The second surgery was performed under emergency conditions for
abdominal pain and large bowel obstruction as reported above. For this
reason, no preoperative diagnosis was made. No intraoperative frozen
section was performed.
Intraoperative findings showed an abdominal mass 20 centimetre
wide infiltrating the uterus and the intestinal wall in addition to
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multiple omental masses and numerous peritoneal nodules. She un-
derwent suboptimal debulking surgery, consisting of a total hyster-
ectomy, omentectomy, left hemicolectomy and rectal resection. The
surgery was sub-optimal due to the large extent of the disease which
involved the abdomen wall and the left ileopsoas muscle. The occur-
rence of deep vein thrombosis and massive peritoneal relapse con-
tributed to a general worsening of the patient's health and of a dete-
rioration of clinical features. The woman deceased after three weeks.
3. Materials and methods
The surgical specimens were formalin-fixed and paraffin embedded.
Immunohistochemistry was performed using primary monoclonal an-
tibodies against Calretinin, Cytokeratin (CK) 5/6, CK7, CK8-18, CK19,
D2-40, WT-1, BAP-1, Estrogen and Progesterone Receptors, PAX-8, Ki-
67, p16, CEA with a Benchmark XT Automating Staining System
(Ventana). Except for BAP-1 (Santa Cruz, 1:70) and Ki-67 (DAKO,
1:100), all the antibodies were provided by Roche company as pre-di-
luted.
4. Results
A histopathological examination of the resected specimens referring
to the abdominal mass infiltrating the large bowel (second surgery)
revealed the presence of polygonal or cuboidal tumour cells with well-
demarcated borders, moderate athypia and variably prominent nu-
cleoli. The mitoses are often present and the neoplasia revealed several
foci of necrosis (Fig. 2A). These features led us to define an histological
diagnosis of epithelioid malignant mesothelioma. This lesion, furtherly
characterized by solid pattern, infiltrated all the specimens and the
intestinal resection margins. Interestingly, there was the presence in the
mass of residual non invasive implants of the previous serous borderline
tumour (Fig. 2B).
The immunohistochemistry revealed differences between the two
tumours. Calretinin was strongly positive in mesothelioma cells while
negative in SBOT and its implants (Fig. 3A and B). Cytokeratin (CK) 5-6
and D2-40 staining were negative in both the tumours. WT1 was focally
and weakly positive only in SBOT cells while BAP-1 showed a greater
positivity in mesothelioma than in SBOT (Fig. 4). Both mesothelioma
and SBOT were positive for PAX-8, CK 7, 8, 18; CK19 showed a focal
staining in very few mesothelioma cells. The proliferative activity was
higher in mesothelioma (90%) than in SBOT (10%). The p53 staining
was positive in the majority of mesothelioma cells but only in scattered
few SBOT cells. The Estrogen and Progesterone receptors resulted to be
positive in SBOT but not in mesothelioma (Fig. 3C). CEA was negative
in both tumours and CA-125 was negative in mesothelioma but positive
in SBOT. p16 was not expressed or a focal expression was seen in SBOT.
Fig. 4 shows a representative staining of several markers. Only on
mesothelioma, S-100 and melanoma cocktail to exclude a metastasis of
melanoma were performed; to exclude GIST, c-kit and DOG-1, and to
exclude a desmoplastic tumour round cells, Caldesmon, desmin and
actin. All these markers revealed to be negative.
5. Discussion
To our knowledge, the presence of both bilateral serous borderline
ovarian tumour (SBOT) and malignant peritoneal mesothelioma has
never been described before in the same woman and in such a tight
temporal connection. We believe that this new association raises nu-
merous issues concerning the origin of the two tumours. Different hy-
potheses could be considered. We think that they may be classified as
metachronous tumours or, a particular and less likely hypothesis could
suggest a common, intended as shared, histogenetic pathway for these
tumours. This can be related to the fact that the ovarian surface epi-
thelium (OSE), the peritoneum, and subjacent connective tissue all
originate from pleuripotential embryonic coelomic epithelium and
subcoelomic mesenchyme (Auersperg et al., 2001). This epithelium, in
the embryonic development, overlies the mesonephros, the mesoder-
mally derived epithelium lining of the intraembrionic coelom. It over-
lies the presumptive gonadal area and, by proliferation and differ-
entiation, gives rise to part of gonadal blastema. In addition, the
coelomic epithelium originates, near the gonads for invagination, the
Mullerian (paramesonephric) ducts, the primordia for the epithelia of
the oviduct, endometrium, and endocervix (Sajjad, 2010). Thus, the
coelomic epithelium in and near the gonadal area represents an em-
bryonic field with the capability of differentiating along many different
pathways. Several differences characterize the two parts of the pelvic
mesothelium; the OSE is less differentiated and less committed to a
mature mesothelial phenotype than the remainder of the pelvic peri-
toneum. CA125 is absent or rarely expressed in OSE while is expressed
in extraovarian mesothelium (Jacobs and Bast Jr., 1989). These
Fig. 1. The figure shows serous borderline tumour referred to the first surgery.
Fig. 2. Malignant mesothelioma (A) referred to the second surgery. Box B depicts the mesothelioma, highlighted by the black arrow, with residual microscopic non invasive implants of
the previous serous borderline tumour with associated psammoma bodies, indicated by the white arrow.
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findings underlight that OSE is closer to its pleuripotential mesodermal
embryonic precursor form than other coelomic epithelial derivatives
(Auersperg et al., 2001). Indeed conventionally, it has been assumed
that the majority of serous epithelial tumours arises from metaplastic
change, with subsequent neoplastic transformation, of the surface epi-
thelium or inclusion cysts (Scully, 1995; Auersperg, 2013) despite al-
ternative tubal origin has been emerged as an important source of high-
grade serous carcinomas (Kurman and Shih, 2011).
In support of this hypothesis, many studies performed on pure
cultures of human OSE transformed by several protocols resulted in
carcinomas and never in mesotheliomas (Sasaki et al., 2009; Zheng
et al., 2010). These remarks emphasize the profound differences in
pleuripotentiality and in response to oncogenic stimuli between OSE,
considered as a modified pelvic mesothelium, and extraovarian
mesothelium. In line with this, the expression of CA125 in OSE-derived
epithelial carcinomas indicates that the adult OSE has retained the
competence of coelomic epithelium to differentiate at least under pa-
thological conditions. However, in our case, further biomolecular stu-
dies are needed to support the hypothesis of a similar source for bi-
lateral borderline serous tumour and mesothelioma, representing a new
association of diseases.
Moreover, although the micropapillary pattern shows more in-
cidence of extraovarian disease and often coexists with invasive im-
plants (Malpica and Wong, 2016), it seems very unlikely that the
neoplastic cells of the borderline tumour have come across a more
aggressive transformation. In our case we just found non invasive im-
plants.
Taken together, these considerations have led us to hypothesize that
Fig. 3. Calretinin immunoreactivity in malignant mesothelioma (A and B, original magnification ×200). Calretinin staining resulted negative in residual non invasive implant pointed out
by the black arrow (B). Estrogen Receptor staining (C, original magnification ×100) was positive in non invasive implant (black arrow) and negative in mesothelioma surrounding the
implant.
Fig. 4. Representative immunohistochemistry of several markers. In all the boxes, mesothelioma and residual non invasive implants of serous borderline tumour are shown to highlight
the difference of staining. (Original magnification ×200, BAP1, PAX8, WT1 and CA125; ×100, CK7 and Ki-67.) The black arrows indicate the implants.
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the mesothelioma is a distinct entity that incorporated the implants
rather than a transformation of the previous one. This is consistent with
what is shown in all the figures.
Because of the differences in the treatment modalities and prog-
nostic implications, diffuse peritoneal malignant mesothelioma should
be distinguished from both ovarian serous neoplasias and primary
peritoneal serous tumours. The differentiation between ovarian carci-
noma and mesothelioma is a particular challenge owing to similarities
in both histological appearances and immunohistochemical profiles.
Calretinin, CK5/6, D2-40 and WT1 are positive in more than 90% of
mesotheliomas; however, they have also been shown to be expressed in
approximately 10%, 25%, 65% and 90% of serous carcinomas, re-
spectively (Kobel et al., 2008; Laury et al., 2010). Our results showed an
absence of positivity of CK5/6, D2-40 and WT1 in mesothelioma cells
with the only positivity of calretinin. A more recent consensus from the
international mesothelioma interest group (Husain et al., 2018) re-
ported that peritoneal mesothelioma presents a less frequent positivity
for CK5/6 (53%–100%) compared to pleural counterpart (75%–100%)
underlining that the immunohistochemical stains are important for the
confirmation of the diagnosis, but a single marker should be interpreted
within the context of the totality of immunohistochemical, morphologic
and clinical findings. Comin et al. (2007) suggest that serous ovarian
tumours and peritoneal mesotheliomas can be distinguished with high
specificity and sensitivity using antibodies to estrogen receptor. Our
findings are consistent with what has been reported leading to consider
these receptors as a good marker of serous tumour.
Laury et al. (2010) reported that PAX8, implicated in the regulation
of the embryonic Mullerian system, permits a distinction between
ovarian tumours and mesothelioma with a focal and weak nuclear po-
sitivity only in the 9% of peritoneal mesothelioma. In our case we found
a positivity of this marker also in mesothelioma.
Moreover, loss of immunohistochemical expression of BAP1 was
reported extremely rarely (0.25%) in gynecological and serous carci-
noma but commonly in abdominal (67%) and thoracic mesothelioma
(47%) (Andrici et al., 2015, 2016). Nevertheless, in our case we found
an opposite result.
In conclusion, we believe this is the first reported case of peritoneal
malignant mesothelioma and bilateral SBOT representing an un-
expected association between diseases. From a clinical point of view,
this case report can be useful to gynaecologists because it leads to re-
commend a careful examination of the peritoneal cavity during a sur-
gical resection of borderline serous tumour. Moreover, it may suggest
performing a close follow-up associated with a careful surveillance of
the patient, especially in the case of micropapillary pattern, to oncol-
ogists. A complete clinical approach could help to detect sooner pos-
sible relapses or other metachronous malignancies.
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